Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04517682 · ClinicalTrials.gov registry record
COVID-19 and SARS-CoV-2 Detection in Saliva
A clinical trial of RNA Virus Infections, sponsored by Ambry Genetics.
- Completed
- Registry status
- 67
- Enrollment target
- 1
- Study location
NCT04517682 is a study of RNA Virus Infections that has completed, run by Ambry Genetics. The registered enrollment target is 67 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04517682, a study of RNA Virus Infections, has completed, sponsored by Ambry Genetics.
- COMPLETED
- Registry status
- 67 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to validate the use of human saliva as a substrate for an assay to detect SARS-CoV-2 and define accuracy, analytical sensitivity and specificity of the TaqPath RT-PCR test.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST RT-PCR
Study Locations (1)
California
- Ambry Genetics - Aliso Viejo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2020-05-21 |
| Est. Completion | 2021-08-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04517682
The ClinicalTrials.gov registry entry for NCT04517682 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ambry Genetics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with RNA Virus Infections appearing as the primary indexed condition, and to 1 intervention - of which RT-PCR is the first listed.
NCT04517682 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04517682 about?
NCT04517682 is a clinical study titled "COVID-19 and SARS-CoV-2 Detection in Saliva". This study aims to validate the use of human saliva as a substrate for an assay to detect SARS-CoV-2 and define accuracy, analytical sensitivity and specificity of the TaqPath RT-PCR test.
What is the current status of trial NCT04517682?
This trial is currently completed. The enrollment target is 67 participants. The study started on 2020-05-21. Estimated completion is 2021-08-05.
What conditions does trial NCT04517682 study?
This clinical trial studies the following conditions: RNA Virus Infections.
What interventions are being tested in trial NCT04517682?
The interventions under investigation include: RT-PCR (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04517682?
This trial is sponsored by Ambry Genetics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04517682 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for RNA Virus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.